Clopidogrel monotherapy is superior to aspirin for secondary prevention in coronary artery disease
1. Major adverse cardiovascular and cerebrovascular events were significantly reduced with clopidogrel compared to aspirin alone. 2. There was no ...
1. Major adverse cardiovascular and cerebrovascular events were significantly reduced with clopidogrel compared to aspirin alone. 2. There was no ...
1. In this systematic review and meta-analysis, de-escalating dual antiplatelet therapy to ticagrelor monotherapy following implantation of a drug-eluting stent ...
Click here to read this study in the Lancet. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...
1. In this systematic review and meta-analysis, the non-vitamin K oral anticoagulants apixaban and dabigatran both had similar rates of ...
1. Ticagrelor was non-inferior to DAPT for the incidence of major adverse cardiovascular and cerebrovascular events. 2. Ticagrelor monotherapy significantly ...
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without ...
1. In patients with an established history of atherosclerotic cardiovascular disease (ASCVD) randomized to either take a daily high (325mg) ...
1. Dual antiplatelet therapy with ticagrelor and asprin led to a significantly lower risk of major adverse cardiovascular events over ...
Click here to read this study in JAMA Ophthalmology. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
1. Clinically relevant bleeding was significantly lower with ticagrelor monotherapy than in the ticagrelor plus aspirin group. 2. Major cardiovascular ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.